News
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be ...
Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QUANTDx™, a new product line of ...
Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
The Company continued further restructuring activities during 2025 including severance, employee-related and facility exit costs. Cost of goods sold includes the benefit received from the sale of ...
Molecular breast imaging (“ MBI ”) is an emerging modality that uses gamma radiation and injectable radioactive tracers. It is typically reserved for investigational diagnostic imaging and delivers a ...
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
Kiniksa is recruiting patients in the dose-focusing portion of the Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis. The company expects data from this portion of the trial in the second ...
BriaPro is a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors ...
Sovateltide, a potential first-in-class, highly selective endothelin-B (ETB) receptor agonist, has previously demonstrated significant improvement in stroke patients compared to standard of care in a ...
The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025. This is related to lower growth expectations for Wegovy ® in the US obesity market, lower growth ...
In April 2025, Radiopharm dosed the first patient in the U.S. Phase 2b imaging study of 18F-RAD101. The multicenter, open-label, single arm Phase 2b clinical trial is evaluating the diagnostic ...
“The meaningful changes seen in a short trial are very encouraging,” said Dr. CJ Barnum, Vice President of CNS Drug Development at INmune Bio. “We are honored that Dr. Sharon Cohen will present our ...
Mike Doustdar has been appointed as the result of a comprehensive process that included external and internal candidates. The Novo Nordisk Foundation fully endorses Novo Nordisk Board’s decision to ...
CHAPEL-EN-LE-FRITH and EDINBURGH, United Kingdom, July 29, 2025 (GLOBE NEWSWIRE) -- Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences industry, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results